Isatis root polysaccharide compound emulsion and preparation method thereof

By preparing isatis polysaccharide into a water-in-water-in-water-type reemulsion, the sustained release and targeted characteristics of the reemulsion technology have been used to solve the problem of insufficient application of isatis polysaccharide in the field of veterinary medicine in the prior art, and the rapid effect has been achieved and the slow and long-term therapeutic effect have improved the bioavailability of the drug and filled the market gap.

CN118924685APending Publication Date: 2024-11-12HENAN UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410975665.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The lack of separate isatis polysaccharide veterinary drugs in the existing market has led to insufficient application in the field of veterinary drugs and is unable to fully utilize the value of isatis polysaccharide.

Method used

Isatis polysaccharide is prepared into a water-in-oil-in-water (W/O/W) compound emulsion by using complex emulsion, combined with sustained release and targeting characteristics, significantly improving the bioavailability and efficacy of the drug. .

Benefits of technology

It has achieved the dual therapeutic effects of isatis polysaccharides with rapid onset and slow long-term effects, filled the gap in market application, improved the bioavailability of drugs, and has stable product properties and strong operationality in production processes, which are suitable for large-scale conversion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924685A_ABST
    Figure CN118924685A_ABST
Patent Text Reader

Abstract

The invention discloses an isatis root polysaccharide compound emulsion. Every 100 g of the compound emulsion is prepared from the following components by weight: 0.1 to 4.0 g of isatis root polysaccharide, 3.0 to 5.0 g of span-60, 1.0 to 3.0 g of polyoxyethylene xylitol anhydride monostearate (PXMS), 8.0 to 16.0 g of soybean oil for injection, 2.0 to 4.0 g of coriander oil, 15.0 to 25.0 g of polyoxyethylene (40) hydrogenated castor oil, 1.0 to 5.0 g of poloxamer 237, 0.01 to 0.1 g of triethanolamine and the balance of water for injection. Meanwhile, the invention further discloses a preparation method of the reemulsion, the finally obtained water-in-oil-in-water (W / O / W) type reemulsion has the characteristics of slow release and targeting after injection, is good in safety and capable of remarkably improving the clinical efficacy of the radix isatidis polysaccharide, the requirement of process conversion on workshops is not high, large-scale production is facilitated, and the application prospect is wide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine and its preparation, and specifically relates to a Radix Isatidis polysaccharide multiple emulsion and a preparation method thereof. Background Art

[0002] Isatis root is the dried root of Isatis indigotica, a cruciferous plant. It is bitter and cold in nature, enters the heart and lung meridians, and has the effects of clearing away heat and detoxifying, cooling blood and relieving sore throat. It is mainly used clinically for the treatment of various heat toxins, plague, yellow sores and swelling, blood heat, sore throat, bloody diarrhea and other diseases. The specific therapeutic effect of Isatis root is related to the various compound components it contains, such as polysaccharides, indigo glycosides, β-sitosterol, indigo red, resin, etc. Among them, Isatis root polysaccharides are of great significance for the prevention and control of infectious diseases. Studies have shown that after being absorbed into the body, polysaccharide components can directly inhibit the replication of viruses, prevent the virus from infecting target cells and protein expression, thereby playing an antiviral role, which is now a consensus in the industry. In order to give full play to the value of Isatis root polysaccharides, various health products such as plant herbal tea beverages and Chinese medicine slices have also appeared on the market in recent years, providing a variety of commodity forms for the value development of Isatis root polysaccharides and promoting the development of human health care.

[0003] The medical and health value of Radix Isatidis polysaccharides is very high, but in the field of veterinary medicines, there are no separate polysaccharide products on the market among the Radix Isatidis related preparations currently circulating in the market, while Astragalus polysaccharides and Lentinan polysaccharides, which belong to the same category of traditional Chinese medicine polysaccharides, have been widely used in the field of veterinary medicines (including injections, oral liquids, powders and other dosage forms). Radix Isatidis polysaccharides are more often used as one of the mixed ingredients of Radix Isatidis extracts in the preparation of traditional Chinese medicine-related preparations, and this application method makes it difficult to give full play to the value of polysaccharides. Therefore, the market needs a separate Radix Isatidis polysaccharide preparation product to fill the gap. Summary of the invention

[0004] In view of the shortcomings of the prior art, the present invention utilizes the multiple emulsion technology to prepare Radix Isatidis polysaccharides into a water-in-oil-in-water (W / O / W) multiple emulsion, which has the dual characteristics of sustained release and targeting. It can significantly improve the bioavailability of the drug when used clinically through intramuscular injection, and the efficacy is significantly enhanced compared with the prior art.

[0005] Specifically, to achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0006] The invention discloses a Radix Isatidis polysaccharide multiple emulsion. The weight composition of each 100g of the multiple emulsion is: 0.1-4.0g of Radix Isatidis polysaccharide, 3.0-5.0g of Span-60, 1.0-3.0g of polyoxyethylene xylitol monostearate (PXMS), 8.0-16.0g of soybean oil for injection, 2.0-4.0g of coriander oil, 15.0-25.0g of polyoxyethylene (40) hydrogenated castor oil, 1.0-5.0g of poloxamer 237, 0.01-0.1g of triethanolamine, and the balance is water for injection.

[0007] Preferably, the weight composition of every 100g of the multiple emulsion is: 0.5-3.5g of Radix Isatidis polysaccharide, 3.5-4.5g of Span-60, 1.2-2.8g of polyoxyethylene xylitol monostearate (PXMS), 9.0-15.0g of soybean oil for injection, 2.5-3.5g of coriander oil, 16.0-24.0g of polyoxyethylene (40) hydrogenated castor oil, 1.5-4.5g of poloxamer 237, 0.02-0.08g of triethanolamine, and the balance is water for injection.

[0008] Further preferably, 2.0 g of Radix Isatidis polysaccharide, 4.0 g of Span-60, 2.0 g of polyoxyethylene xylitol monostearate (PXMS), 12.0 g of soybean oil for injection, 3.0 g of coriander oil, 20.0 g of polyoxyethylene (40) hydrogenated castor oil, 3.0 g of poloxamer 237, 0.05 g of triethanolamine, and 53.95 g of water for injection.

[0009] The present invention further discloses a method for preparing the Radix Isatidis polysaccharide multiple emulsion, comprising the following steps:

[0010] (a) dissolving Radix Isatidis polysaccharide in a formula amount of water for injection at a temperature of 0 to 10° C., taking out 5 to 25% of the polysaccharide, adding it to a mixture of Span-60, polyoxyethylene xylitol monostearate (PXMS), soybean oil for injection and coriander oil, stirring evenly, and then performing ultrasonic emulsification of the system at a frequency of 28 kHz, stirring during emulsification, and controlling the temperature of the system at 0 to 10° C. throughout the process, to obtain an opaque uniform system with a milky yellow or light brown appearance, which is recorded as System 1;

[0011] (b) at room temperature, firstly mix polyoxyethylene (40) hydrogenated castor oil, poloxamer 237 and the remaining 75-95% Radix Isatidis polysaccharide solution prepared in step (a), and after the system becomes homogeneous and transparent, add system 1 and mix evenly, which is recorded as system 2;

[0012] (c) At room temperature, homogenize and emulsify system 2 until the system is transformed into a milky yellow or light brown opaque uniform emulsion, add triethanolamine and mix evenly, sterilize and package to obtain the product.

[0013] In the final system of the present invention, the main ingredient Radix Isatidis polysaccharide exists in the form of "multiple emulsion" as a carrier, one part exists in the internal aqueous phase in the form of oil-in-water (W / O), and the other part exists in the external aqueous phase in the form of water-in-oil-in-water (W / O / W), and can exert its efficacy through two absorption pathways after injection. The first part can form a local "drug depot" after coating because the outer layer is an oil layer, which has the characteristics of sustained release and long-acting, and the particle size is at the nanometer level, and it also has a certain targeting. The outer layer of the second part is a water layer, which can be quickly absorbed after injection and quickly dispersed to the tissues throughout the body through blood flow, thereby achieving the effect of quickly treating the disease. Through the technical improvement of Radix Isatidis polysaccharide in the present invention, the dual therapeutic effects of "rapid onset" and "slow and long-acting" can be achieved clinically, filling the market application gap of Radix Isatidis polysaccharide.

[0014] In the prescription of the present invention, Radix Isatidis polysaccharide is the main component, and the others are auxiliary components. The functions of each auxiliary component are:

[0015] 1) Span-60 and polyoxyethylene xylitol monostearate are selected as the ingredients of the present invention. The laboratory screened a large number of emulsifiers with hydrophilic-lipophilic balance (HLB) values ​​lower than 8.0 and found that the mixed phase formed by the two ingredients is suitable for the emulsification of Radix Isatidis polysaccharides. First, the combination of the two emulsifiers is in a liquid state with good fluidity throughout the preparation process, while other emulsifiers will have a paste-like "viscous" state in the middle, which makes it difficult to mix the materials. Second, the samples prepared by the emulsifier combination can meet the stability requirements of long-term storage at -20 to 40°C without demulsification. In addition, it is highly inert and does not chemically react with the main component, so it is selected;

[0016] 2) The combination of soybean oil and coriander oil for injection is selected as the component of the present invention because through experimental investigation, when the two form a water-in-oil (W / O) system in the early stage, the combination of soybean oil and coriander oil is evaluated from three perspectives: stability, fluidity, and the morphology of the drug particles after coating. At the same time, from the perspective of production transformation and promotion and application, both raw materials have strict maturity standards, which is convenient for checking from the source. In addition, the combination does not irritate the injection site, has strong tissue compatibility, good absorption, and does not form pustules or nodules;

[0017] 3) Polyoxyethylene (40) hydrogenated castor oil and poloxamer 237 are selected as the components of the present invention, mainly because the combination is observed to be more stable and safe when the secondary coating forms a water-in-oil-in-water (W / O / W) system;

[0018] 4) Triethanolamine is selected as an essential component of the present invention because it has a great auxiliary effect on maintaining the shape of the emulsion droplets through experiments. If it is removed, the emulsion droplets are prone to adhesion (Comparative Examples 2 and Figure 5 ), which causes the emulsion to precipitate and become unstable.

[0019] In the preparation method of the present invention, step (a) is to complete the emulsification process under a low temperature environment of 0 to 10°C using a low-frequency ultrasound of 28KHZ. This process is conducive to forming a stable oil-in-water type primary emulsion, thereby paving the way for secondary water-in-oil emulsification, and ultimately obtaining a more stable emulsion system. Too high a temperature or too high an ultrasonic frequency will cause the system to obtain additional energy, which can easily lead to the rupture of the formed emulsion droplets, and the final emulsion system is prone to stratification, affecting the stability of the emulsion (Comparative Examples 1 and Figure 4 ).

[0020] Compared with the prior art, the present invention achieves the following technical effects through the improvement of formulation and process:

[0021] (1) The Radix Isatidis polysaccharide multiple emulsion of the present invention is of the water-in-oil-in-water type (W / O / W), and has the characteristics of rapid onset, sustained release, long-term effect, and targeting, which greatly improves the bioavailability of the drug;

[0022] (2) The Radix Isatidis polysaccharide multiple emulsion of the present invention fills the gap in the current market technology of Radix Isatidis polysaccharide emulsion preparations, and is expected to replace the existing Radix Isatidis injection products for promotion in the future;

[0023] (3) The product of the present invention has stable properties, strong operability of production process technology, and is conducive to large-scale transformation. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is an electron microscope photograph of the first-level water-in-oil emulsion prepared in step (a) of the double emulsion of the present invention (Example 1);

[0025] Figure 2 This is a photograph of the final appearance of the double emulsion sample of the present invention (Example 1);

[0026] Figure 3 This is an electron microscope photograph of the water-in-oil-in-water sample system of the double emulsion of the present invention (Example 1);

[0027] Figure 4 This is a photo of the appearance of the sample system being unstable and having upper and lower layers;

[0028] Figure 5 This is an electron microscope micrograph of the sample after the triethanolamine is removed according to the preparation method of Example 1. DETAILED DESCRIPTION

[0029] The present invention will be further described below by means of specific examples, but these specific embodiments do not limit the protection scope of the present invention in any way.

[0030] Examples 1-10

[0031] To make the specification concise, the weight composition of the Radix Isatidis polysaccharide multiple emulsion of the present invention described in Examples 1-10 is given below in the form of a table, as shown in Table 1.

[0032] Table 1 Weight composition per 100g of the present invention in Examples 1-10

[0033]

[0034] The method for preparing the Radix Isatidis polysaccharide multiple emulsion described in Example 1 comprises the following steps:

[0035] (a) dissolving 2.0 g of Radix Isatidis polysaccharide in 53.95 g of water for injection at 0-10° C., taking out 12.0 g (accounting for 21.4% of the total amount of the Radix Isatidis polysaccharide solution) after stirring and dissolving, and mixing it into a mixture consisting of 4.0 g of Span-60, 2.0 g of polyoxyethylene xylitol monostearate (PXMS), 12.0 g of soybean oil for injection and 3.0 g of coriander oil, stirring evenly, placing the system in an ultrasonic instrument and performing ultrasonic emulsification at a frequency of 28 kHz, stirring while emulsifying, and controlling the temperature of the system at 0-10° C. throughout the process to obtain an opaque uniform system 1 having a milky yellow appearance;

[0036] (b) at room temperature, 20.0 g of polyoxyethylene (40) hydrogenated castor oil, 3.0 g of poloxamer 237 and the remaining 43.95 g of Radix Isatidis polysaccharide solution from step (a) were mixed, and after the system became homogeneous and transparent, system 1 was added and mixed to obtain system 2;

[0037] (c) At room temperature, homogenize and emulsify system 2 until the system is transformed into a milky yellow opaque uniform emulsion, add 0.05 g of triethanolamine, stir evenly, sterilize and package to obtain the product.

[0038] In each operation step of Example 1, system 1 is a water-in-oil (W / O) system. Figure 1 The outer dark area is the oil phase, the inner bright area is the water phase, and the particle size distribution is between 0.1 and 2.2 μm. The final system is a water-in-oil-in-water (W / O / W) type, and the appearance is a milky yellow system (such as Figure 2 ), electron microscope observation Figure 3 The dark area is the oil phase of oil-in-water, the bright area is the external water phase, and the particle size distribution is between 0.5 and 20.0 μm.

[0039] The preparation methods of the Radix Isatidis polysaccharide multiple emulsions described in Examples 2 to 10 are the same as those in Example 1.

[0040] In other embodiments, after the Radix Isatidis polysaccharide is dissolved in step (a), the amount of the Radix Isatidis polysaccharide solution in system 1 is 5-25% of the total amount of the Radix Isatidis polysaccharide solution, and the effects of the present invention can be achieved.

[0041] Comparative experiment

[0042] Comparative Example 1: Effect of increasing the emulsification temperature and the ultrasonic frequency in step (a) on the present invention

[0043] In the Radix Isatidis polysaccharide multiple emulsion of the present invention, step (a) needs to be emulsified in a low temperature environment and under low-frequency ultrasonic conditions, otherwise the prepared primary emulsion will be unstable, resulting in the final system prepared from the secondary emulsion being prone to demulsification and stratification during the later storage process (such as Figure 4 ).

[0044] According to the formulation and preparation process of Example 1, the temperature of the emulsification system in step (a) was controlled at 5°C, 15°C, 25°C and 35°C, respectively, and the operations of steps (b) and (c) remained unchanged. The prepared sample was placed in a constant temperature and humidity environment at a temperature of 40°C and a relative humidity of 70% for accelerated stability investigation. The appearance of the drug solution was observed on the 1st, 7th, 15th, 30th, 60th and 90th day, respectively. The results are shown in Table 2.

[0045] The ultrasonic frequencies of step (a) were set at 28 kHz, 33 kHz, 40 kHz and 80 kHz, respectively, the system temperature was controlled at about 5°C, the operations of steps (b) and (c) remained unchanged, and the prepared samples were placed in a constant temperature and humidity environment at a temperature of 40°C and a relative humidity of 70% for accelerated stability investigation. The stratification of the drug solution was observed at 1 d, 7 d, 15 d, 30 d, 60 d and 90 d, respectively. The results are shown in Table 3.

[0046] Table 2 Effect of different emulsification temperatures in step (a) on the final emulsion system of Radix Isatidis polysaccharides

[0047]

[0048]

[0049] The results show that the higher the emulsification temperature, the earlier the stratification time of the final emulsion system is; the longer it is stored, the more serious the stratification is and the worse the stability is.

[0050] Table 3 Effect of different ultrasonic frequencies in step (a) on the final system of Radix Isatidis polysaccharide emulsion

[0051]

[0052] The results show that the higher the ultrasonic frequency, the earlier the stratification time of the final emulsion system is prepared; the longer it is stored, the more serious the stratification is and the worse the stability is.

[0053] Comparative Example 2: Effect of triethanolamine on the system of the present invention

[0054] Triethanolamine is an essential component of the present invention and is crucial to maintaining the stability of the system. Taking the formulation and preparation steps of Example 1 as an example, after the system is uniformly emulsified in step (c), triethanolamine is not added and the system is directly sterilized and packaged. The sample is placed in a constant temperature and humidity environment at a temperature of 40°C and a relative humidity of 70% for continuous accelerated observation for one month. Finally, flocculent precipitation is observed in the sample, and adhesion between the emulsion droplets can be observed under an electron microscope ( Figure 5 ).

[0055] The results show that triethanolamine plays a key role in maintaining the stability of the Radix Isatidis polysaccharide emulsion system of the present invention and is an essential component of the present invention.

[0056] Test Example 1 Stability Test

[0057] The Radix Isatidis polysaccharide multiple emulsion samples prepared in Examples 1-10 were investigated according to the pharmaceutical stability evaluation standard. All samples were sealed in transparent glass bottles and placed in different temperature environments of 40°C, 25°C, 4°C and -20°C. At the same time, in order to reduce the test error, the number of samples of each example at different temperatures was not less than 10. Samples were taken and observed at 1d, 7d, 15d, 30d, 60d, 90d, 120d and 180d after the start of the test to see if demulsification such as stratification, precipitation, discoloration, etc. occurred.

[0058] Test results: All samples of the examples at 40°C, 25°C and 4°C maintained their original properties at every point during the inspection period, without any unstable phenomena such as stratification, precipitation, discoloration, etc. All samples stored at -20°C froze, but thawed quickly after returning to room temperature, and the entire emulsion system did not experience any demulsification such as stratification, precipitation, discoloration, etc.

[0059] The results show that the Radix Isatidis polysaccharide emulsion of the present invention has good stability.

[0060] Test Example 2 Safety Test

[0061] In order to enable the present invention to be rapidly promoted in the clinic, the inventor directly selected the target animal pig as the test object. The experimental pig breed is Du Dachang Sanyuan nursery pig, weighing about 20kg, from the same farm and the same batch, with a number of 40, randomly divided into 4 groups, 10 in each group, half male and half female. Group 1 is the control group, each head is intramuscularly injected with 5.0ml of normal saline, and groups 2, 3, and 4 are the low-dose, medium-dose and high-dose groups tested in the present invention, each head is intramuscularly injected with 2.5ml, 5.0ml and 10.0ml of the Radix Isatidis polysaccharide emulsion prepared in Example 1, and the injection site is unified as the left side of the neck, and the medication is used once in the morning and evening every day for 7 consecutive days.

[0062] In order to reduce errors, each group of experimental pigs was managed by the same breeder during the experiment and raised in the same environment. The characteristic changes of the medication site were observed every day, and the animals' feeding, drinking and other behaviors were recorded. If a pig dies, it must be dissected as soon as possible to observe the lesions of various organs. If there is no death, each group will randomly select 2 males and 2 females for autopsy after the end of the experiment, and keep records. The results are shown in Table 4.

[0063] Table 4 Safety test of Radix Isatidis polysaccharide multiple emulsion of the present invention

[0064]

[0065]

[0066] Result analysis:

[0067] 1) The Radix Isatidis polysaccharide multiple emulsion of the present invention, whether it is a low dose, a medium dose, or a high dose, under the experimental conditions of twice daily use for 7 consecutive days, the injection site of each group of pigs has only slight redness and swelling (a normal phenomenon of injection medication), without pustules or bleeding. The redness and swelling can recover on their own within 2 days after the end of the test, and there is no difference between the test group and the control group, indicating that the local irritation evaluation of the present invention is qualified.

[0068] 2) No pigs in each group died during the test period, and there were no significant differences in the average daily water intake and feed intake among the groups. The behavior was also good, no different from that of healthy pigs, indicating that the systemic safety of the double emulsion of the present invention is also qualified.

[0069] After the experiment, 2 male and 2 female pigs were randomly selected from each group for autopsy. The results showed that the brain, lungs, heart, liver, kidney, spleen, stomach, duodenum, jejunum, ileum, cecum, colon and rectum of each group of pigs were normal, with good coagulation, and there was no significant difference among the groups.

[0070] The results show that the Radix Isatidis polysaccharide multiple emulsion of the present invention has good clinical safety.

[0071] Test Example 3: Efficacy Test

[0072] The inventors evaluated the efficacy of influenza treatment in laying hens in Luoyang, Henan. The experimental chicken farm has 50,000 chickens, which are raised in a single building. The breed is Hy-Line Brown, 233 days old, and the average weight is 2012.1g. The sick chickens showed swollen heads, poor breathing, foam in the nostrils, yellow-green feces, listlessness, and a 11.3% decrease in feed intake. As of the day before the test, the morbidity rate of the whole group was 8.4%, and the mortality rate was 1.7%. The autopsy of dead chickens showed bleeding of glandular stomach papillae, swelling of gizzards, and the crop was full of foul-smelling liquid. The lymph follicles in the middle of the duodenum, near the yolk pedicle of the jejunum, and the ileum were swollen and hemorrhaged. Blood samples were taken for laboratory examination and found to be infected with H9N2 influenza virus.

[0073] 200 sick chickens with similar disease severity in the flock were selected as test subjects and divided into 4 groups, each with 50 chickens. Group 1 was the control group, and no treatment measures were taken; Group 2 was the prior art product Radix Isatidis injection group, and each chicken was intramuscularly injected with 1.0 ml of the national standard Radix Isatidis injection, once in the morning and evening, twice a day; Group 3 was the common Radix Isatidis polysaccharide group (dissolved Radix Isatidis polysaccharide in water for injection to prepare 2% injection, filtered, sterilized, and packaged), each chicken was intramuscularly injected with 1.0 ml in the chest, once in the morning and evening, twice a day; Group 4 was the Radix Isatidis polysaccharide emulsion group of the present invention (Example 1), each chicken was intramuscularly injected with 1.0 ml in the chest, only in the morning, once a day. Each group of chickens was isolated in the same environment and cared for by the same administrator for 5 consecutive days of treatment, during which the recovery of each group of chickens was observed and recorded.

[0074] Rehabilitation evaluation criteria:

[0075] Death: If sick chickens die during treatment, -1 point;

[0076] Ineffective: Although the sick chickens did not die during the treatment, the symptoms did not improve, 0 points;

[0077] Outcome: The symptoms of the sick chickens were alleviated during the treatment, but they have not fully recovered, 1 point;

[0078] Cure: After treatment, all symptoms of the sick chickens disappear, and their behavior is no different from that of healthy chickens, 2 points;

[0079] Cure rate: the ratio of the number of cured individuals to the total number of test chickens in this group × 100%;

[0080] Total effective rate: the ratio of the total number of individuals that have recovered and been cured to the total number of test chickens in this group × 100%.

[0081] Table 5 Clinical efficacy test of Radix Isatidis polysaccharide multiple emulsion of the present invention

[0082]

[0083] Result analysis:

[0084] 1) Group 1 did not use any drug treatment and allowed the disease to develop naturally. Eventually, 23 died, 3 were ineffective, and recovered through their own resistance. Eventually, 14 recovered, 10 were cured, and scored 11 points. The cure rate and total effective rate were low, at 20% and 48%, respectively. Groups 2, 3, and 4 scored 40, 57, and 64 points higher than Group 1, respectively, with cure rates of 32%, 48%, and 52%, respectively, and total effective rates of 22%, 32%, and 38%, respectively, indicating that Radix Isatidis injection and Radix Isatidis polysaccharide preparations have strong anti-influenza virus effects.

[0085] 2) Compared with Group 2 and Group 3, using the same dose of drug, Group 3 scored 17 points higher, and the cure rate and total effective rate were 16% and 10% higher than Group 2, respectively, indicating that simple Radix Isatidis polysaccharide is more effective against influenza virus.

[0086] 3) Group 4 was compared with Group 3. The daily dosage of Radix Isatidis polysaccharide in Group 3 was twice that of Group 4, but the final effect was inferior to that of Group 4. Compared with Group 3, Group 4 scored 7 points higher, and the cure rate and total effective rate were 4% and 6% higher, respectively. This shows that after Radix Isatidis polysaccharide was prepared into a multiple emulsion, the bioavailability of the drug was significantly improved through the rapid effect, sustained release and targeting of the preparation.

[0087] The results show that the anti-influenza virus efficacy of Radix Isatidis polysaccharide emulsion is better than similar existing products.

Claims

1. A Radix Isatidis polysaccharide multiple emulsion, characterized in that: The weight composition of each 100g of the double emulsion is: 0.1-4.0g of Radix Isatidis polysaccharide, 3.0-5.0g of Span-60, 1.0-3.0g of polyoxyethylene xylitol monostearate (PXMS), 8.0-16.0g of soybean oil for injection, 2.0-4.0g of coriander oil, 15.0-25.0g of polyoxyethylene (40) hydrogenated castor oil, 1.0-5.0g of poloxamer 237, 0.01-0.1g of triethanolamine, and the balance is water for injection.

2. The Radix Isatidis polysaccharide multiple emulsion according to claim 1, characterized in that: The weight composition of each 100g of the multiple emulsion is: 0.5-3.5g of Radix Isatidis polysaccharide, 3.5-4.5g of Span-60, 1.2-2.8g of polyoxyethylene xylitol monostearate (PXMS), 9.0-15.0g of soybean oil for injection, 2.5-3.5g of coriander oil, 16.0-24.0g of polyoxyethylene (40) hydrogenated castor oil, 1.5-4.5g of poloxamer 237, 0.02-0.08g of triethanolamine, and the balance is water for injection.

3. The Radix Isatidis polysaccharide multiple emulsion according to claim 2, characterized in that: The weight composition of each 100g of the double emulsion is: 2.0g of Radix Isatidis polysaccharide, 4.0g of Span-60, 2.0g of polyoxyethylene xylitol monostearate (PXMS), 12.0g of soybean oil for injection, 3.0g of coriander oil, 20.0g of polyoxyethylene (40) hydrogenated castor oil, 3.0g of poloxamer 237, 0.05g of triethanolamine, and 53.95g of water for injection.

4. The Radix Isatidis polysaccharide multiple emulsion according to any one of claims 1 to 3, characterized in that: The double emulsion is of the water-in-oil-in-water (W / O / W) type.

5. The method for preparing the Radix Isatidis polysaccharide multiple emulsion according to any one of claims 1 to 3, characterized in that: The following steps are involved: (a) Dissolving Radix Isatidis polysaccharide in a formula amount of water for injection at 0-10° C. to obtain a Radix Isatidis polysaccharide solution, taking out 5-25% of the total amount of the Radix Isatidis polysaccharide solution and adding it to a mixture of Span-60, polyoxyethylene xylitol monostearate (PXMS), soybean oil for injection and coriander oil, stirring evenly, and then performing ultrasonic emulsification at a frequency of 28 kHz, stirring during emulsification, and controlling the system temperature at 0-10° C. throughout the process, to obtain an opaque uniform system with a milky yellow or light brown appearance, which is recorded as System 1; (b) At room temperature, the remaining Radix Isatidis polysaccharide solution was mixed with polyoxyethylene (40) hydrogenated castor oil and poloxamer 237. After the system became homogeneous and transparent, the system 1 was added and mixed evenly, which was recorded as system 2. (c) At room temperature, homogenize and emulsify system 2 until the system turns into a milky yellow or light brown opaque uniform emulsion, add triethanolamine and mix evenly, sterilize and package to obtain the product.